NasdaqGS:IMVTBiotechs
A Look At Immunovant (IMVT) Valuation After Batoclimab Phase 3 Failure And Refocus On IMVT-1402
Immunovant (IMVT) is back in focus after reporting that two Phase 3 studies of batoclimab in thyroid eye disease did not meet their primary endpoint, prompting a shift in attention toward its IMVT-1402 program.
See our latest analysis for Immunovant.
Despite the batoclimab setback, Immunovant’s recent 1-day and 7-day share price returns of 1.59% and 5.69% suggest some near term optimism. Its 72.97% 1-year total shareholder return keeps the longer term story firmly in focus.
If you are...